Weekly signal · AXSM · Healthcare

Axsome Therapeutics Inc (AXSM) pushes 12-week advance to 62.6%

The CNS-focused biotech remains in an active trend, but confirmation is measured rather than broad-based.

Axsome Therapeutics Inc
Latest255.17 USD
1W move9.8%
Volume1.0x
TrendActive
Biotechnology market chart visual for Axsome Therapeutics stock.

Market update

What happened

Axsome Therapeutics Inc (AXSM) finished the latest weekly period at 255.17 USD, adding 9.8% for the week and 12.1% over four weeks in weekly market data.

The 52-week weekly price path shows the advance extending, while volume was close to normal at 3.44 million shares versus a 13-week average of 3.48 million. Market Dynamics showed positive confirmation at 1.15, while Relative Strength at 41.2 left the setup short of a stronger momentum reading.

Continue your research

Explore AXSM across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

AXSM coverage

Evidence context